Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04SQJ
|
|||
| Former ID |
DIB012916
|
|||
| Drug Name |
EW-A-401
|
|||
| Indication | Peripheral vascular disease [ICD-11: BD4Z; ICD-10: I73.9; ICD-9: 443.9] | Phase 1 | [1] | |
| Company |
Sangamo BioSciences
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vascular endothelial growth factor receptor 1 (FLT-1) | Target Info | Modulator | [2] |
| KEGG Pathway | Ras signaling pathway | |||
| Rap1 signaling pathway | ||||
| Cytokine-cytokine receptor interaction | ||||
| HIF-1 signaling pathway | ||||
| Endocytosis | ||||
| PI3K-Akt signaling pathway | ||||
| Focal adhesion | ||||
| Transcriptional misregulation in cancer | ||||
| Rheumatoid arthritis | ||||
| Pathway Interaction Database | Glypican 1 network | |||
| HIF-2-alpha transcription factor network | ||||
| S1P3 pathway | ||||
| VEGF and VEGFR signaling network | ||||
| VEGFR1 specific signals | ||||
| Signaling events mediated by VEGFR1 and VEGFR2 | ||||
| Reactome | Neurophilin interactions with VEGF and VEGFR | |||
| VEGF binds to VEGFR leading to receptor dimerization | ||||
| WikiPathways | Focal Adhesion | |||
| Signaling by VEGF | ||||
| Angiogenesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00080392) EW-A-401 to Treat Intermittent Claudication. U.S. National Institutes of Health. | |||
| REF 2 | DOI: http://dx.doi.org/10.1016/j.tips.2014.09.007 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.